Maarten van der Doelen

Immunophenotyping during radium-223 therapy in mCRPC patients

ID−01 ID−02 ID−03 ID−04 ID−05 ID−06 ID−07 ID−08 ID−09 ID−10 ID−11 ID−12 ID−13 ID−14 ID−15 ID−16 ID−17 ID−18 ID−19 ID−20 ID−21 ID−22 ID−23 ID−24 ID−25 ID−26 ID−27 ID−28 ID−29 ID−30

Patient

3

BL

2

4

6

Injection number

Supplementary figure 2. Availability of PBMCs for immunophenotyping per injection. A grey rectangle indicates the availability of PBMCs at baseline (BL), or after the second, fourth, or sixth radium-223 injection.

A

B

Hemoglobin

Platelets

4 5 6 7 8 9 10

100 150 200 250 300 350 400

Cells (x10 9 /L)

Hb (mmol/L)

BL 1 2 3 4 5 6 Injection number

BL 1 2 3 4 5 6 Injection number

Supplementary figure 3. Normalized absolute hemoglobin and platelet levels during radium-223 treatment. A . Hemoglobin (slope: -0.20 mmol/L per injection number, 95% CI: -0.23 - -0.17) at baseline (BL) and after each radium-223 injection. B . Platelet levels (slope: -4.35 * 10 9 cells/L, 95% CI: -7.26 - -1.44) at baseline (BL) and after each radium-223 injection. Red dots indicate the group means. The blue line represents the fitted linear regression model, including 95% CI.

79